Literature DB >> 8359676

Construction of genetically marked Vibrio cholerae O1 vaccine strains.

J M Ketley1, J Michalski, J Galen, M M Levine, J B Kaper.   

Abstract

Attenuated Vibrio cholerae O1 vaccine strains lacking the gene encoding the A subunit of cholera toxin have proven efficacious in preventing experimental cholera. As these strains move from closed, contained testing environments to large-scale field trials, a readily assayable phenotypic trait to distinguish a vaccine strain from wild-type V. cholerae O1 is desirable. We have constructed three derivatives of the attenuated V. cholerae strain CVD 103 which carry a mercury resistance or urease marker in the hlyA gene. CVD 103-HgR was constructed using a protracted marker-exchange procedure; this strain was found to have somewhat lowered colonisation efficiency in infant mice in comparison to its parent strain, CVD 103. The insertion of the resistance marker was repeated using a suicide vector system; CVD 103-HgR2 was found to colonise infant mice as efficiently as CVD 103. Strain CVD 103-UR, in which sequences encoding urease were inserted using a suicide vector, also colonised infant mice as well as CVD 103. The genetically marked strains CVD 103-HgR, CVD 103-HgR2 and CVD 103-UR form the basis for a generation of defined oral vaccines that may give single-dose, long-lasting protection to populations at risk from cholera.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8359676     DOI: 10.1111/j.1574-6968.1993.tb06355.x

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  24 in total

1.  Prolonged colonization of mice by Vibrio cholerae El Tor O1 depends on accessory toxins.

Authors:  Verena Olivier; Nita H Salzman; Karla J Fullner Satchell
Journal:  Infect Immun       Date:  2007-08-13       Impact factor: 3.441

2.  Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks.

Authors:  Wilbur H Chen; Richard N Greenberg; Marcela F Pasetti; Sofie Livio; Michael Lock; Marc Gurwith; Myron M Levine
Journal:  Clin Vaccine Immunol       Date:  2013-10-30

3.  Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design.

Authors:  Charles H Jones; Anders P Hakansson; Blaine A Pfeifer
Journal:  J Mater Chem B       Date:  2014-09-12       Impact factor: 6.331

4.  An overview of VaxchoraTM, a live attenuated oral cholera vaccine.

Authors:  Tarun Saluja; Vijayalaxmi V Mogasale; Jean-Louis Excler; Jerome H Kim; Vittal Mogasale
Journal:  Hum Vaccin Immunother       Date:  2019-09-20       Impact factor: 3.452

5.  The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae.

Authors:  Leslie M Mayo-Smith; Jakub K Simon; Wilbur H Chen; Douglas Haney; Michael Lock; Caroline E Lyon; Stephen B Calderwood; Beth D Kirkpatrick; Mitchell Cohen; Myron M Levine; Marc Gurwith; Jason B Harris
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

Review 6.  Cholera.

Authors:  J B Kaper; J G Morris; M M Levine
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

7.  The OmpU outer membrane protein, a potential adherence factor of Vibrio cholerae.

Authors:  V Sperandio; J A Girón; W D Silveira; J B Kaper
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

8.  CVD110, an attenuated Vibrio cholerae O1 El Tor live oral vaccine strain.

Authors:  J Michalski; J E Galen; A Fasano; J B Kaper
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

Review 9.  Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine.

Authors:  Myron M Levine
Journal:  BMC Biol       Date:  2010-10-04       Impact factor: 7.431

10.  Development of a live oral attaching and effacing Escherichia coli vaccine candidate using Vibrio cholerae CVD 103-HgR as antigen vector.

Authors:  Rogeria Keller; Tamara D Hilton; Hernam Rios; Edgar C Boedeker; James B Kaper
Journal:  Microb Pathog       Date:  2009-10-28       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.